PHAR investigators, in collaboration with Akcea Therapeutics and Ionis Pharmaceuticals, conducted a claims analysis on patients newly diagnosed with transthyretin amyloidosis (ATTR) using Medicare Research Identifiable Files, characterizing selected conditions, symptoms, and healthcare utilization during the three years prior to diagnosis. Their findings help fill a gap in the literature on the patient journey prior to diagnosis of ATTR, which may facilitate earlier diagnosis and treatment. The article was published online ahead of print in the Journal of Comparative Effectiveness Research and can be found on PHAR’s publications page.